查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2019784

眼科疾病治療市場規模、佔有率、成長率及全球產業分析：按類型、應用和地區分類，並預測至2026-2034年

Ophthalmic Disease Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 180 Pages | 商品交期: 請詢問到貨日

價格

眼科疾病治療市場成長要素

受眼科疾病率上升和對先進治療方案需求不斷成長的推動，全球眼科藥物市場正穩步成長。預計到2025年，該市場規模將達到400.9億美元，2026年將成長至426.1億美元，到2034年將達到715.8億美元。這一成長反映了眼科藥物研發的持續進步以及全球眼部健康意識的不斷提高。

眼科藥物包括用於治療青光眼、乾眼症、視網膜疾病和眼部感染疾病等疾病的藥物和治療方法。這些疾病負擔日益加重，尤其是在高齡化社會中，是推動市場擴張的主要因素。

市場趨勢

塑造市場格局的關鍵趨勢之一是對先進藥物輸送系統的日益重視。傳統的眼科治療常面臨藥物吸收率低、藥物快速從體內排放等挑戰。為了克服這些挑戰，各公司正投資研發創新解決方案，例如基於奈米技術的製劑、緩釋植入和藥物緩釋隱形眼鏡。

此外，基因療法和生物製藥的應用日益普及。這些先進治療方法提供標靶治療方案，改善患者預後並減少給藥頻率。人工智慧（AI）在診斷和治療方案製定中的應用也推動了市場的發展。

市場成長要素

眼科疾病治療市場的主要驅動力是眼科疾病發生率的上升。由於人口老化和生活方式的改變，青光眼和老齡化黃斑部病變等疾病變得越來越常見。螢幕使用時間的增加和環境因素也是導致視力問題的原因。

另一個主要因素是研發投入的增加。製藥公司正積極研發新藥和新治療方法，以滿足尚未滿足的醫療需求。臨床試驗和監管核准的增加正在加速產品上市，並拓寬治療選擇。

此外，醫療保健支出增加和眼科醫療保健服務可近性的提高，促使全球診斷和治療率上升，從而進一步促進了市場成長。

抑制因子

儘管市場成長前景強勁，但也面臨許多挑戰。生物製藥和先進治療方法的高成本仍然是一大障礙，尤其是在發展中地區。許多患者難以負擔這些治療費用，導致治療順從性降低。

此外，新興國家醫療衛生基礎設施匱乏，以及公眾意識不足，阻礙了早期診斷和治療。這些因素造成了患者群體與現有治療方案之間的差距，從而減緩了整體市場滲透率。

細分分析

按藥物分類

市場區隔包括抗發炎藥、感染疾病、抗血管內皮生長因子（VEGF）藥、抗青光眼藥及其他藥物。預計到2026年，抗發炎藥物將佔較大的市場佔有率，這主要得益於對治療方法眼部發炎和過敏藥物的高需求。同時，隨著視網膜疾病病例的增加，抗VEGF療法預計將快速成長。

按劑型

根據劑型，市場包括液體製劑、固態和半固態製劑。由於半固體製劑具有更長的藥物停留時間和更高的療效，預計到2026年，半固態製劑將佔市場主導地位，市場佔有率將達到79.59%。液體製劑因其給藥方便仍被廣泛使用。

疾病特異性

受糖尿病視網膜病變和老齡化黃斑部病變病例不斷增加的影響，視網膜疾病預計將在2026年成為該細分市場的主要促進因素，佔33.94%的市場佔有率。乾眼症和青光眼細分市場也在穩定成長。

透過分銷管道

受數位化進步和購藥便利性提高的推動，預計到 2026 年，零售藥局和線上藥局將主導市場，佔 89.97% 的市場佔有率。

區域趨勢

北美佔最大的市場佔有率，預計到 2025 年將達到 43.37%（市場規模為 173.9 億美元），到 2026 年將擴大到 184.8 億美元。該地區受益於強大的醫療保健基礎設施、較高的健康意識和新藥認證。

歐洲是第二大市場，主要受人口老化和眼科疾病率上升的驅動。亞太地區預計將成為成長最快的地區，這得益於醫療保健投資的增加和患者意識的提高。

拉丁美洲、中東和非洲的市場正在逐步擴大，這得益於醫療保健服務的改善和先進治療方法的廣泛應用。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 主要眼科疾病盛行率：依主要國家分類，2025 年
  • 主要企業管道分析
  • 主要企業專利概覽
  • 產業重大發展動態－併購與合作
  • 主要國家的監管狀況
  • 主要國家的還款狀況
  • 新冠疫情對市場的影響

第5章：2021-2034年全球眼科疾病治療市場分析、洞察與預測

  • 市場分析、洞察與預測：按藥物類別分類
    • 抗發炎藥
    • 抗感染藥物
    • Anti-VEGF
    • 青光眼藥物
      • BETA阻斷劑
      • 前列腺素類似物
      • α腎上腺素促效劑
      • 碳酸酐酶抑制劑
      • 同時服用的藥物
      • 其他
    • 其他
  • 市場分析、洞察與預測：按劑型分類
    • 固體的
    • 液體
    • 半固態製劑
  • 市場分析、洞察與預測：按適用疾病分類。
    • 青光眼
      • 開放性青光眼
      • 隅角閉鎖性青光眼
      • 其他
    • 乾眼症
    • 視網膜疾病
      • 糖尿病黃斑部水腫（DME）
      • 黃斑部病變（AMD）
      • 糖尿病視網膜病變（DR）
      • 視網膜靜脈阻塞（RVO）
      • 其他
    • 過敏及感染疾病
    • 其他
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 實體店和網路藥局
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美眼科疾病治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲眼科疾病治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太眼科疾病治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲眼科疾病治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲眼科疾病治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Viatris Inc.
    • Novartis AG
    • AbbVie Inc.
    • F. Hoffmann-La Roche Ltd.
    • Regeneron Pharmaceuticals, Inc.
    • Santen Pharmaceutical Co., Ltd.
    • Bayer AG
    • Bausch & Lomb Incorporated
    • Merck KGaA
Product Code: FBI100441

Growth Factors of ophthalmic disease therapeutics Market

The global ophthalmic disease therapeutics market is witnessing steady growth driven by the increasing prevalence of eye-related disorders and rising demand for advanced treatment solutions. The market was valued at USD 40.09 billion in 2025 and is expected to grow to USD 42.61 billion in 2026, reaching USD 71.58 billion by 2034. This growth reflects continuous advancements in ophthalmic drug development and increasing awareness regarding eye health worldwide.

Ophthalmic therapeutics include drugs and treatments designed to manage conditions such as glaucoma, dry eye disease, retinal disorders, and ocular infections. The rising burden of these diseases, especially among the aging population, is significantly contributing to the expansion of the market.

Market Trends

A key trend shaping the market is the growing focus on advanced drug delivery systems. Traditional eye treatments often face limitations due to poor drug absorption and rapid elimination. To overcome these challenges, companies are investing in innovative solutions such as nanotechnology-based formulations, sustained-release implants, and drug-eluting contact lenses.

Additionally, the adoption of gene therapies and biologics is increasing. These advanced therapies offer targeted treatment options, improving patient outcomes and reducing the frequency of administration. The integration of artificial intelligence in diagnosis and treatment planning is also supporting the market's evolution.

Market Growth Drivers

The primary factor driving the ophthalmic disease therapeutics market is the rising prevalence of eye disorders. Conditions such as glaucoma and macular degeneration are becoming more common due to aging populations and lifestyle changes. Increasing screen time and environmental factors further contribute to vision-related problems.

Another major driver is the growing investment in research and development. Pharmaceutical companies are actively developing novel drugs and therapies to address unmet medical needs. The increasing number of clinical trials and regulatory approvals is accelerating product launches and expanding treatment options.

Moreover, rising healthcare expenditure and improved access to eye care services are boosting diagnosis and treatment rates globally, further supporting market growth.

Restraining Factors

Despite strong growth prospects, the market faces certain challenges. The high cost of biologics and advanced therapies remains a significant barrier, particularly in developing regions. Many patients struggle with affordability, leading to lower treatment adherence.

Additionally, lack of awareness and limited access to healthcare infrastructure in emerging economies restricts early diagnosis and treatment. These factors create a gap between the patient population and available therapeutic solutions, slowing overall market adoption.

Segmentation Analysis

By Drug Class

The market is segmented into anti-inflammatory, anti-infectives, anti-VEGF, anti-glaucoma, and others. The anti-inflammatory segment holds a significant share in 2026, driven by high demand for treatments addressing ocular inflammation and allergies. Meanwhile, anti-VEGF therapies are expected to grow rapidly due to increasing cases of retinal diseases.

By Dosage Form

Based on dosage form, the market includes liquid, solid, and semisolid formulations. The semisolid segment dominates with 79.59% share in 2026, owing to its prolonged drug retention and effectiveness. Liquid forms remain widely used due to ease of administration.

By Disease Indication

Retinal diseases lead the segment with a 33.94% market share in 2026, driven by rising cases of diabetic retinopathy and macular degeneration. Dry eye disease and glaucoma segments are also expanding steadily.

By Distribution Channel

Retail and online pharmacies dominate the market with 89.97% share in 2026, supported by increasing digital adoption and convenience in purchasing medications.

Regional Insights

North America holds the largest share, accounting for 43.37% in 2025, with a market value of USD 17.39 billion, rising to USD 18.48 billion in 2026. The region benefits from strong healthcare infrastructure, high awareness, and continuous product approvals.

Europe follows as the second-largest market, driven by an aging population and increasing prevalence of eye diseases. Asia Pacific is expected to witness the fastest growth due to rising healthcare investments and growing patient awareness.

Latin America and the Middle East & Africa are gradually expanding, supported by improving healthcare access and increasing adoption of advanced therapies.

Conclusion

The ophthalmic disease therapeutics market is set for robust growth from USD 40.09 billion in 2025 to USD 71.58 billion by 2034, driven by rising prevalence of eye disorders, technological advancements, and increasing R&D activities. While high treatment costs and limited awareness in emerging regions pose challenges, ongoing innovations and expanding healthcare access are expected to bridge these gaps. Overall, the market presents significant opportunities for stakeholders, with continuous advancements shaping the future of eye care globally.

Segmentation By Drug Class

  • Anti-inflammatory
  • Anti-infectives
  • Anti-VEGF
  • Anti-glaucoma
    • Beta Blockers
    • Prostaglandins Analogs
    • Alpha Adrenergic Agonists
    • Carbonic Anhydrase Inhibitors
    • Combination Drugs
    • Others
  • Others

By Dosage Form

  • Solid
  • Liquid
  • Semisolid

By Disease Indication

  • Glaucoma
    • Open Angle Glaucoma
    • Angle Closure Glaucoma
    • Others
  • Dry Eye Disease
  • Retinal Diseases
    • Diabetic Macular Edema (DME)
    • Macular Degeneration (AMD)
    • Diabetic Retinopathy (DR)
    • Retinal Vein Occlusion (RVO)
    • Others
  • Allergy & Infections
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail & Online Pharmacies

By Region

  • North America (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Major Ophthalmic Diseases, in Key Countries/ Region, 2025
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Patent Snapshot, By Key Players
  • 4.4. Key Industry Developments - Merges, Acquisitions and Partnerships
  • 4.5. Regulatory Scenario for Key Countries
  • 4.6. Reimbursement Scenario for Key Countries
  • 4.7. Impact of COVID-19 on the Market

5. Global Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Anti-inflammatory
    • 5.1.2. Anti-infectives
    • 5.1.3. Anti-VEGF
    • 5.1.4. Anti-glaucoma
      • 5.1.4.1. Beta Blockers
      • 5.1.4.2. Prostaglandins Analogs
      • 5.1.4.3. Alpha Adrenergic Agonists
      • 5.1.4.4. Carbonic Anhydrase Inhibitors
      • 5.1.4.5. Combination Drugs
      • 5.1.4.6. Others
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 5.2.1. Solid
    • 5.2.2. Liquid
    • 5.2.3. Semisolid
  • 5.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.3.1. Glaucoma
      • 5.3.1.1. Open Angle Glaucoma
      • 5.3.1.2. Angle Closure Glaucoma
      • 5.3.1.3. Others
    • 5.3.2. Dry Eye Disease
    • 5.3.3. Retinal Diseases
      • 5.3.3.1. Diabetic Macular Edema (DME)
      • 5.3.3.2. Macular Degeneration (AMD)
      • 5.3.3.3. Diabetic Retinopathy (DR)
      • 5.3.3.4. Retinal Vein Occlusion (RVO)
      • 5.3.3.5. Others
    • 5.3.4. Allergy & Infections
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail & Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Anti-inflammatory
    • 6.1.2. Anti-infectives
    • 6.1.3. Anti-VEGF
    • 6.1.4. Anti-glaucoma
      • 6.1.4.1. Beta Blockers
      • 6.1.4.2. Prostaglandins Analogs
      • 6.1.4.3. Alpha Adrenergic Agonists
      • 6.1.4.4. Carbonic Anhydrase Inhibitors
      • 6.1.4.5. Combination Drugs
      • 6.1.4.6. Others
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 6.2.1. Solid
    • 6.2.2. Liquid
    • 6.2.3. Semisolid
  • 6.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.3.1. Glaucoma
      • 6.3.1.1. Open Angle Glaucoma
      • 6.3.1.2. Angle Closure Glaucoma
      • 6.3.1.3. Others
    • 6.3.2. Dry Eye Disease
    • 6.3.3. Retinal Diseases
      • 6.3.3.1. Diabetic Macular Edema (DME)
      • 6.3.3.2. Macular Degeneration (AMD)
      • 6.3.3.3. Diabetic Retinopathy (DR)
      • 6.3.3.4. Retinal Vein Occlusion (RVO)
      • 6.3.3.5. Others
    • 6.3.4. Allergy & Infections
    • 6.3.5. Others
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail & Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Anti-inflammatory
    • 7.1.2. Anti-infectives
    • 7.1.3. Anti-VEGF
    • 7.1.4. Anti-glaucoma
      • 7.1.4.1. Beta Blockers
      • 7.1.4.2. Prostaglandins Analogs
      • 7.1.4.3. Alpha Adrenergic Agonists
      • 7.1.4.4. Carbonic Anhydrase Inhibitors
      • 7.1.4.5. Combination Drugs
      • 7.1.4.6. Others
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 7.2.1. Solid
    • 7.2.2. Liquid
    • 7.2.3. Semisolid
  • 7.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.3.1. Glaucoma
      • 7.3.1.1. Open Angle Glaucoma
      • 7.3.1.2. Angle Closure Glaucoma
      • 7.3.1.3. Others
    • 7.3.2. Dry Eye Disease
    • 7.3.3. Retinal Diseases
      • 7.3.3.1. Diabetic Macular Edema (DME)
      • 7.3.3.2. Macular Degeneration (AMD)
      • 7.3.3.3. Diabetic Retinopathy (DR)
      • 7.3.3.4. Retinal Vein Occlusion (RVO)
      • 7.3.3.5. Others
    • 7.3.4. Allergy & Infections
    • 7.3.5. Others
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail & Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.5.1. U.K
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Anti-inflammatory
    • 8.1.2. Anti-infectives
    • 8.1.3. Anti-VEGF
    • 8.1.4. Anti-glaucoma
      • 8.1.4.1. Beta Blockers
      • 8.1.4.2. Prostaglandins Analogs
      • 8.1.4.3. Alpha Adrenergic Agonists
      • 8.1.4.4. Carbonic Anhydrase Inhibitors
      • 8.1.4.5. Combination Drugs
      • 8.1.4.6. Others
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 8.2.1. Solid
    • 8.2.2. Liquid
    • 8.2.3. Semisolid
  • 8.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.3.1. Glaucoma
      • 8.3.1.1. Open Angle Glaucoma
      • 8.3.1.2. Angle Closure Glaucoma
      • 8.3.1.3. Others
    • 8.3.2. Dry Eye Disease
    • 8.3.3. Retinal Diseases
      • 8.3.3.1. Diabetic Macular Edema (DME)
      • 8.3.3.2. Macular Degeneration (AMD)
      • 8.3.3.3. Diabetic Retinopathy (DR)
      • 8.3.3.4. Retinal Vein Occlusion (RVO)
      • 8.3.3.5. Others
    • 8.3.4. Allergy & Infections
    • 8.3.5. Others
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail & Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Anti-inflammatory
    • 9.1.2. Anti-infectives
    • 9.1.3. Anti-VEGF
    • 9.1.4. Anti-glaucoma
      • 9.1.4.1. Beta Blockers
      • 9.1.4.2. Prostaglandins Analogs
      • 9.1.4.3. Alpha Adrenergic Agonists
      • 9.1.4.4. Carbonic Anhydrase Inhibitors
      • 9.1.4.5. Combination Drugs
      • 9.1.4.6. Others
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 9.2.1. Solid
    • 9.2.2. Liquid
    • 9.2.3. Semisolid
  • 9.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.3.1. Glaucoma
      • 9.3.1.1. Open Angle Glaucoma
      • 9.3.1.2. Angle Closure Glaucoma
      • 9.3.1.3. Others
    • 9.3.2. Dry Eye Disease
    • 9.3.3. Retinal Diseases
      • 9.3.3.1. Diabetic Macular Edema (DME)
      • 9.3.3.2. Macular Degeneration (AMD)
      • 9.3.3.3. Diabetic Retinopathy (DR)
      • 9.3.3.4. Retinal Vein Occlusion (RVO)
      • 9.3.3.5. Others
    • 9.3.4. Allergy & Infections
    • 9.3.5. Others
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail & Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Anti-inflammatory
    • 10.1.2. Anti-infectives
    • 10.1.3. Anti-VEGF
    • 10.1.4. Anti-glaucoma
      • 10.1.4.1. Beta Blockers
      • 10.1.4.2. Prostaglandins Analogs
      • 10.1.4.3. Alpha Adrenergic Agonists
      • 10.1.4.4. Carbonic Anhydrase Inhibitors
      • 10.1.4.5. Combination Drugs
      • 10.1.4.6. Others
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 10.2.1. Solid
    • 10.2.2. Liquid
    • 10.2.3. Semisolid
  • 10.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.3.1. Glaucoma
      • 10.3.1.1. Open Angle Glaucoma
      • 10.3.1.2. Angle Closure Glaucoma
      • 10.3.1.3. Others
    • 10.3.2. Dry Eye Disease
    • 10.3.3. Retinal Diseases
      • 10.3.3.1. Diabetic Macular Edema (DME)
      • 10.3.3.2. Macular Degeneration (AMD)
      • 10.3.3.3. Diabetic Retinopathy (DR)
      • 10.3.3.4. Retinal Vein Occlusion (RVO)
      • 10.3.3.5. Others
    • 10.3.4. Allergy & Infections
    • 10.3.5. Others
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail & Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Viatris Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Novartis AG
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. AbbVie Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. F. Hoffmann-La Roche Ltd.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Regeneron Pharmaceuticals, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Santen Pharmaceutical Co., Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Bayer AG
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Bausch & Lomb Incorporated
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Merck KGaA
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2021-2034
  • Table 3: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
  • Table 4: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 5: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2021-2034
  • Table 6: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2021-2034
  • Table 7: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 9: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 10: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2021-2034
  • Table 11: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
  • Table 12: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 13: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2021-2034
  • Table 14: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2021-2034
  • Table 15: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 17: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 18: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2021-2034
  • Table 19: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
  • Table 20: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 21: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2021-2034
  • Table 22: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2021-2034
  • Table 23: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 25: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 26: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2021-2034
  • Table 27: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
  • Table 28: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 29: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2021-2034
  • Table 30: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2021-2034
  • Table 31: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 32: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 33: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 34: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2021-2034
  • Table 35: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
  • Table 36: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 37: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2021-2034
  • Table 38: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2021-2034
  • Table 39: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 40: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 41: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 42: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2021-2034
  • Table 43: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
  • Table 44: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 45: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2021-2034
  • Table 46: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2021-2034
  • Table 47: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 48: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Ophthalmic Disease Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2025 & 2034
  • Figure 4: Global Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2025 & 2034
  • Figure 5: Global Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Ophthalmic Disease Therapeutics Market Value (USD billion), by Region, 2025 & 2034
  • Figure 7: North America Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 8: North America Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 9: North America Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2025 & 2034
  • Figure 10: North America Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2025
  • Figure 11: North America Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 12: North America Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2025
  • Figure 13: North America Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Ophthalmic Disease Therapeutics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Ophthalmic Disease Therapeutics Market Value Share (%), By Country, 2025
  • Figure 17: Europe Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 18: Europe Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 19: Europe Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2025 & 2034
  • Figure 20: Europe Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2025
  • Figure 21: Europe Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 22: Europe Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2025
  • Figure 23: Europe Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Ophthalmic Disease Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Ophthalmic Disease Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 28: Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 29: Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2025 & 2034
  • Figure 30: Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2025
  • Figure 31: Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 32: Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2025
  • Figure 33: Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 38: Latin America Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 39: Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2025 & 2034
  • Figure 40: Latin America Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2025
  • Figure 41: Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 42: Latin America Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2025
  • Figure 43: Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Ophthalmic Disease Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 48: Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 49: Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2025 & 2034
  • Figure 50: Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2025
  • Figure 51: Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 52: Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2025
  • Figure 53: Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Ophthalmic Disease Therapeutics Market Share (%), By Company, 2025